Clinical Trials Directory

Trials / Completed

CompletedNCT02442804

Cognitive Impact of Pomegranate Polyphenols Following Ischemic Stroke

The Effects of Pomegranate Polyphenols on Neuropsychological Functioning Following Ischemic Stroke

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
16 (actual)
Sponsor
Loma Linda University · Academic / Other
Sex
All
Age
18 Years – 89 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether pomegranate supplements improve cognitive functioning following stroke.

Detailed description

Research suggests that antioxidants (substances that may slow or prevent cell damage) found in many fruits and vegetables may help improve brain functioning (for example, memory and attention) in healthy individuals and prevent cognitive decline in individuals who have suffered a stroke. The purpose of this research study is to examine whether dietary supplementation with an antioxidant extract can help promote healthy cognitive functioning as a component of recovery after stroke. The procedures include: Administering polyphenols via 2 POMx pills, each of which contains polyphenols derived from pomegranates equivalent to the content of approximately 8 ounces of pomegranate juice, or placebo pills (capsules containing no polyphenol ingredients), every day for one week to inpatients who are in the acute post-stroke phase. Neuropsychological testing pre- and post-treatment will determine whether cognitive functioning changes. Subjects will be randomized into either a placebo or polyphenol group.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPOMxPomegranate supplement (1g) by mouth twice per day for 7 days
OTHERPlaceboPlacebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days

Timeline

Start date
2015-06-01
Primary completion
2016-04-01
Completion
2016-04-01
First posted
2015-05-13
Last updated
2017-08-02
Results posted
2017-08-02

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02442804. Inclusion in this directory is not an endorsement.